Collaboration – WP4

Home  /  Outputs   /  Collaboration – WP4

EUnetHTA recently started a new Joint Assessment on a medicinal product for secondary progressive MS. To find out about participation, please read more here. Input submissions will be received through till EOB, April 28th.

Please see the below Final Project Plan of the Fourth Pharma Joint Assessment on 'sotagliflozin for adult patients with Type 1 Diabetes Mellitus who have inadequate blood glucose control using insulin or insulin analogues.' Timelines will change slightly due to the

The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)” is now available. We are pleased to announce that the collaborative rapid assessment on “C-reactive

We are pleased to announce that the collaborative rapid assessment, OTCA16, on “BIORESORBABLE STENTS FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS (CORONARY ARTERY DISEASE)” is now available. The health technology assessed is a device for percutaneous coronary intervention (PCI). The objective of

This is the final project plan of the assessment on C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs) and the comments provided by external experts during scoping. OTCA12_Final-project-plan.pdf OTCA12_Draft-project-plan_collated-comments-from-external-experts_fact_check_manufacturers.pdf

We are pleased to announce publication of the collaborative assessment OTCA09 "High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer". This is the assessment of the relative effectiveness of high-intensity focused ultrasound (HIFU) ablation for the treatment of prostate